KR910002810A - 안지오텐신 ii 길항제로서의 치환된 퀴나졸리논 - Google Patents
안지오텐신 ii 길항제로서의 치환된 퀴나졸리논 Download PDFInfo
- Publication number
- KR910002810A KR910002810A KR1019900009994A KR900009994A KR910002810A KR 910002810 A KR910002810 A KR 910002810A KR 1019900009994 A KR1019900009994 A KR 1019900009994A KR 900009994 A KR900009994 A KR 900009994A KR 910002810 A KR910002810 A KR 910002810A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- aryl
- defined above
- alkenyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.상기식에서, L은 J 또는 K와 연결되어 하기에서 정의하는 바와 같은 방향족 환을 형성하고: J는 -C(=M)-이거나, J 및 L이 함께 연결되어, R7a, R7b, R8a, 및 R8b로 치환된 6-탄소 방향족 환을 형성하고, 단, J 및 K중하나만이 -C(=M)-이며: K는 -C(=M)-이거나, K 및 L이 함께 연결되어 R7a, R7b, R8a, 및 R8b로 치환된 6-탄소 방향족 환을 형성하고, 단, J 및 K중 하나만이 -C(=M)-이고: M은 산소 또는 NR22이며 :R1은(a)CO2R4, (b) -SO2R5, (c) -NHSO2CH3, (d) -PO(OR5)2, (e) -SO2-NH-R9, (f) -CONHOR5, (g), (h), (i) 하기에서 정의하는 바와같은 -O2NH-헤테로아릴, (j) 하기에서 정의하는 바와같은 -CH2SO2NH-헤테로아릴, (k) -SO2NH-CO-R23, (l) -CH2SO2NH-CO-R23(m) -CONH-SO2R23, (n) -CH2CONH-SO2R23, (o)-NHSO2NHCO-R23, (p) -NHCONHSO2-R23,이고 (여기서, 헤테로아릴은 O, N 또는 S로 이루어진 그룹중에서 선택된 1내지 3개의 헤테로원자를 임의로 함유할수 있는 비치환, 임치환 또는 이치환된 5-또는 6-원 방향족 환이며, 치환체들은 -OH, -SH, -C1-C4알킬, -C1-C4-알콕시, -CF3할로(Cl, Br, F, I), -NO2, -CO2H, -CO2-(C1-C4-알킬), -NH2, -NH(C1-C4-알킬) 및 -N(C1-C4-알킬)2로 이루어진 그룹에서 선택된 원소이다): R2a, 및 R2b각각 독립적으로 (a) H, (b) 할로겐(Cl, Br, I, F), (c) NO2, (d) NH2, (e) C1-C4-알킬아미노, (f) 디(C1-C4-알킬)아미노, (g) SO2NHR9, (h) CF, (i) C1-C6-알킬, (j) C1-C6-알콕시, (k) C1-C6-알킬-S- (l) C2-C6-알케닐, (m) C2-C6-알키닐, (n) 하기 정의하는 바와 같은 아릴, (o) 아릴 (C1-C4-알킬), 또는 (p) C3-C7-사이클로알킬이며:R3a(a) H, (b) 할로 (Cl, Br, I, F), (c) C1-C6-알킬, (d) C1-C6-알콕시, 또는 (e) C1-C6-알콕시알킬이고: R3b(a) H, (b) 할로 (Cl, Br, I, F), (c) NO2, (d) C1-C6-알킬 (e) C1-C6-아실옥시, (f) C3-C7-사이크로알킬, (g) C1-C6-알콕시, (h) -NHSO2R4, (i) 하이드록시-(C1-C4-알킬), (j) 아릴-(C1-C4-알킬), (k) C1-C4-알킬티오, (l) C1-C4-알킬설피닐, (m) C1-C4-알킬설포닐 (n) NH2, (o) C1-C4-알킬아미노, (p) 디(C1-C4-알킬)아미노, (q) 플루오로-C1-C4-알킬, (r) -SO2-NHR9, (s) 하기에서 정의한 바와 같은 아릴, (t) 푸릴, (u) CF3, (v) C2-C6-알케닐, 또는 (w) C2-C6-알키닐이고 (여기서, 아릴은 할로겐(Cl, Br, I, F), N(R4)2, CO2R4, C1-C4-알킬, C1-C4-알콕시, NO2, CF3, C1-C4-알킬티오, 및 OH로 이루어진 그룹중에서 선택된 1또는 2개의 치환체로 임의로 치환된 페닐 또는 나프틸이다); R4는 수소, 상기에서 정의 한 바와 같은 아릴이거나 상기에서 정의한 바와 같은 아릴로 임의 치환된 직쇄 또는 측쇄 C1-C6알킬이며; R4a는 상기에서 정의한 바와 같은 아릴이거나 상기에서 정의한 바와 같은 아릴로 임의 치환된 직쇄 또는 측쇄 C1-C6-알킬이고; R5는 H또는이며; E는 단일 결합, -NR13(CH2)3-, -S(O)x(CH2)3-(여기서 x는 0내지 2이고, s는 0내지 5이다), -CH(OH)- -O-, CO-이고; R6은 (a) 할로(Cl, Br, I, F), -O-C1-C4알킬, C1-C4-알킬, -NO2, -CF3-SO2NR9R10, -S-C1-C4-알킬, -OH, -NH2, C3-C7사이클로알킬, 및 C3-C10-알케닐로 이루어진 그룹중에서 선택된 1또는 2개의 치환체로 임의 치환된 상기에서 정의한 바와 같은 아릴, (b) 각각이 상기에서 정의한 바와 같은 아릴, C3-C7-사이클로알킬, 할로 (Cl, Br, I, F)-OR4, CF3, CF2CF3, -NH2, -NH(C1-C4알킬), -N(C1-C4-알킬)2, -NH-SO2R4-COOR4및 -SO2NHR9로 이루어진 그룹중에서 선택된 치환체로 임의 치환될 수 있는 직쇄 또는 측쇄 C1-C6알킬, C2-C5알케닐 또는 C2-C5-알키닐. (c) N,O 및 S로 이루어진 그룹중에서 선택된 1또는 2개의 원소를 함유할 수 있는 비치환, 일치환 또는 이치환된 헤테로방향족 5-또는 6-원 사이클릭 환(여기서, 치환체는 -OH, -SH, C1-C4알킬, C1-C4-알콕시,-CF3, 할로(Cl, Br, I, F) 및 NO2로 이루어진 그룹중에서 선택된다): (d) C3-C7-사이클로알킬, (e) 피플루오로 C1-C4-알킬, 또는 (f) H이며:R7a및 R7b는 독립적으로 (a) H, (b) 직쇄 또는 측쇄 C1-C6-알킬, C2-C6-알케닐 또는 C2-C6-알케닐, (c) 할로 (Cl, Br, I, F), (d) CF3, 또는 (e) R7a및 R7b가 인접한 탄소원자에 결합된 경우, 이들은 연결되어 페닐환을 형성할 수 있고; R5a및 R8b는 독립적으로 (a) H, (b)-OH, -구아니디노, C1-C4-알콕시, -N(R4b, COOR4, -CON(R4)2, -O-COR4, -아릴, 헤테로아릴, -S-(O)x-R23, -테트라졸-5-일, -CONHSO2R23, -SO2NH-헤테로아릴, -SO2NHCOR23, -PO(OR4)2, -PO(OR4)R9, -SO2NH-CN 및 NR10COOR23으로 이루어진 그룹중에서 선택된 치환체로 임의 치환된 C1-C6-알킬, (c) -CO-아릴, (d) -C3-C7-사이클로알킬, (e)-할로 (Cl, Br, I, F), (f)-OH, (g) -OR23, (h) -C1-C4-퍼플로오로알킬, (i)-S(O)x-R23, (j) -COOR4, (k)-SO3H, (l)-NR4R23, (m)-NR4COR23,(n)-NR4COOR23, (o) -SO2NR9R10, (P)-NO2, (q) -N(R4)SO2R23, (r) -NR4CONR4R23, (g), (t) 상기에서 정의한 바와 같은 -아릴 또는 헤테로아릴, (u) -NHSO2CF3, (v) -SO2NH-헤테로아릴, (w)-SO2NHCOR23, (x)-CONHSO2R23, (y) -PO(OR4)2, (z)-PO(OR4)2, (aa)-테트라졸-5-일. (bb)-CONH(테트라졸-5-일). (cc)-COR4, (dd) -SO2NHCN, 또는 (ee)(여기서, n은 0또는 1이다) 이며: R9은 H, C1-C5-알킬, 아릴 또는 아릴메틸이고; R10은 H또는 C1-C4-알킬이며; R″은 H, C1-C6알킬, C1-C4-알케닐, C1-C4-알콕시알킬 또는이고; R12는 -CN, -NO2또는 -CO2R4이며; R13은 H, (C1-C4-알킬)CO-, C1-C6-알킬, 알릴, C3-C6-사이클로알킬, 아릴 또는 아릴메틸이고; R14는 H, C1-C8-알킬, C1-C8-피플루오로알킬, C3-C6-사이클로알킬, 아릴 또는 아릴메틸이며; R15는 H, C1-C6-알킬이고; R16은 H, C1-C6-알킬, C3-C6사이클로알킬아릴 또는 아릴메틸이며; R17은 -NR9R10, -OR10, -NHCONH2, -NHCSNH2,-NHSO2 또는 -NHSO2 이고, R18및 R19는 독립적으로 C1-C4-알킬이거나 이들이 함께는 -(CH2)q-형성되며(단, g는 2또는 3이다); R20은 H, -NO2, -NH2, -OH또는 -OCH3이고; R21은 H, 아릴, 또는 아릴, -NH2, -NH(C1-C4알킬), -N(C1-C4알킬)2, -CO2R4, -OH, -SO3H 또는 -SO2NH2에 의해 임의 치환된 C1-C4-알킬이며 ; R22는 (a) 상기에서 정의한 아릴, (b) 상기에서 정의한 헤테로아릴, 또는 (c) 상기에서 정의한 아릴, 상기에서 정의한 ㅎ테로아릴, -OH, -NH2, -NH(C1-C4-알킬)-N(C1-C4-알킬)2, -CO2R4, 할로(Cl, Br, F, I), 및 -CF3로 이루어진 그룹중에서 선택된 치환체에 의해 임의 치환된 C1-C4알킬이고; R23은 (a)상기에서 정의한 아릴, (b) 상기에서 정의한 헤테로아릴, (c) C3-C7-사이클로알킬, (d) 상기에서 정의한 아릴, 상기에서 정의한 헤테로아릴, -OH, -SH, C1-C4-알킬, -O(C1-C4알킬), -S(C1-C4-알킬), -CF3, 할로(Cl, Br, F, I), -NO2, -CO2H, CO2-C1-C4-알킬, -NH2, -NH(C1-C4-알킬), -N-(C1-C4-알킬)2, PO3H2, -PO(OH)(O-C1-C4-알킬) 및 -PO(OR4)R9로 이루어진 그룹중에서 선택된 치환체에 의해 임의 치환된 C1-C6-알킬, 또는 (e)퍼플루오로-C1-C4-알킬이며; X는 (a) 탄소-탄소 단일 결합, (b) -CO-, (c) -O-, (d) -S-, (e) -N-, R13(f) -CON-, R15(g) -NCO-, R15(h) -OCH2-, (i) -CH2O-, (j) -SCH2-, (k) -CH2S-, (l) -NHC(R9)(R10), (m) -NR9SO2-, (n) -SO2NR9-, (o) -C(R9)(R10)NH-, (p) -CH=CH-, (q) -CF=CF-, (r) -CH=CF-, (s) -CF=CH-, (t) -CH2CH2-, (u) -CF2CF2-,또는(w) , (x)(y)또는 (z)이고; r은 1 또는 2이다.
- 제1항에 있어서, J가 -C(O)-이고:K 및 L이 함께 결합하여 R7a, R7b, R8a및 R8b로 치환된 6-탄소 방향족환이며; R1은 (a) -COOH, (b), (c)-NH-SO2CF3, (d) 상기에서 정의한 -SO2NH-헤테로아릴, (e) 상기에서 정의한 -CH2-SO2NH-헤테로아릴, (f) -SO2NH-CO-R23, (g) -CH2SO2NH-CO-R23, (h) -CONH-SO2R23, (i) -CH2CONH-SO2R23, (j) -NHSO2NHCO-R23또는 (k)- NHCONHSO2-R23이고; R2a는 H이며; R2b는 H, F, Cl, CF3, C1-C6-알킬, C2-C4-알케닐, 또는, C2-C4-알키닐이고; R3a는 H이며: R3b는 H, F. Cl, CF3, C1-C6-알킬, C2-C4-알케닐, C2-C4-알키닐, C5-C6-사이클로알킬, -COOCH3, -COOC2H5, -SO2-CH3, NH2, -N(C1-C4-알킬)2또는 -NH-SO2CH3이고; E는 단일결합, -O-또는 -S-이며; R6는 (a) C3-C5-사이클로알킬, Cl, CF3-COL3, -O-CH3, -OC2H5, -S-CH3, -S-C2H5, 페닐 및 F로 이루어진 그룹중에서 선택된 치환체로 임의 치환된 C1-C5알킬, (a) H, (b) COOR4, OCOR4a, OH, 또는 아릴로 임의 치환된 C1-C4알킬, (c) C2-C4-알케닐, (d) OH, (e) -NO2, (f), (g) -C1-C4-알콕시, (h) -NR4-C-OR23, (i) -NR4R23, (j) -할로 (Cl, F, Br), (k) -CF3, (l) -CO2R4, (m) 상기에서 정의한 바와 같은 -CO-아릴, (n) -S(O)x-C1-C4-알킬, (o) -SO2-NH-C1-C4-알킬, (p) 상기에서 정의한 바와 같은 -SO2-NH-아릴 (q)SO2CH3(r) 상기에서 정의한 바와 같은 -아릴, 또는 (s) -NR4-CONR4R23이고 ; X는 C-C 단일 결합이며; r은 1인 화합물,
- 제1항에 있어서, K는 -C(O)-이고; J 및 K 은 함께 연결되어 R7a, R8a및 R8a로 치환된 6-탄소 방향족환을 형성하며; (b), (c)-NH-SO2CF3, (d) 상기에서 정의하는 바와 같은 -SO2NH-헤테로아릴, (e) 상기에서 정의하는 바와 같은 -CH2-SO2NH-헤테로아릴, (f) -SO2NH-CO-R23, (g) -CH2SO2NH-CO-R23, (h) -CONH-SO2R23, (i) -CH2CONH-SO2R23, (j) -NHSO2NHCO-R23또는 (k)- NHCONHSO2-R23이고; R2a는 H이며; R2b는 H, F, Cl, CF3, C1-C6-알킬, C2-C4-알케닐, 또는 C2-C4-알키닐이고; R3a는 H이며; R3b는 H, F. Cl, CF3, C1-C6-알킬, C2-C4-알케닐, C2-C4-알키닐, C5-C6-사이클로알킬, -COOCH3, -COOC2H5, -SO2-CH3, NH2, -N(C1-C4-알킬)2또는 -NH-SO2CH3이고; E는 단일결합, -O-또는 -S-이며; R6는 (a) 메틸, 에틸, Cl, CF3-CCl3, -O-CH3, -S-CH3, -OC2H5, -S-C2H5, 페닐 및 F로 이루어진 그룹중에서 선택된 치환체로 임의 치환된 C1-C5알킬, (b) C2-C5-알케닐 또는 C2-C5-알키닐; 또는 (c) C3-C5-사이클로알킬이고; R7a및 R7b는 각각 H이며, R8a및 R8b는 독립적으로 (a) H, (b) COOR4, OCOR4, OH, 또는 아릴로 임의 치환된 C1-C4알킬, (c) C2-C4-알케닐, (d) OH, (e) -NO2, (f), (g) -C1-C4-알콕시, (h), (i) -NR4R23, (j) -할로 (Cl, F, Br), (k) -CF3, (l) -CO2R4, (m) 상기에서 정의한 바와 같은 -CO-아릴, (n) -S(O)x-C1-C4-알킬, (o) -SO2-NH-C1-C4-알킬, (p) 상기에서 정의한 바와 같은 -SO2-NH-아릴 (q)(r) 상기에서 정의한 바와 같은 -아릴, 또는 (s) -NR4-CONR4R23이고 ; X는 C-C 단일 결합이며; r은 1인 일반식 (I)의 화합물.
- 제1항에 있어서, K가 -C(=NR22)-이고; J 및 L은 함께 연결되어 R7a, R7b, R8a및 R8b로 치환된 6-탄소 방향족 환을 형성하며; R1은 (a) COOH, (b)(c)-NH-SO2CF3, (d) 상기에서 정의하는 바와 같은 -SO2NH-헤테로아릴, (e) 상기에서 정의하는 바와 같은 -CH2-SO2NH-헤테로아릴, (f) -SO2NH-CO-R23, (g) -CH2SO2NH-CO-R23, (h) -CONH-SO2R23, (i) -CH2CONH-SO2R23, (j) -NHSO2NHCO-R23또는 (k)- NHCONHSO2-R23이고; R2a는 H이며; R2b는 H, F, Cl, CF3, C1-C6-알킬, C2-C4-알케닐, 또는 C2-C4-알키닐이고; R3a는 H이며; R3b는 H, F. Cl, CF3, C1-C6-알킬, C2-C4-알케닐, C2-C4-알키닐, C5-C6-사이클로알킬, -COOCH3, -COOC2H5, -SO2-CH3, NH2, -N(C1-C4-알킬)2또는 -NH-SO2CH3이고; E는 단일결합, -O-또는 -S-이며; R6는 (a) C3-C5-사이클로알킬, Cl, CF3-CCl3, -O-CH3, -OC2H5, -S-CH3, -S-C2H5또는 페닐 및 F로 이루어진 그룹중에서 선택된 치환체로 임의 치환된 C1-C5알킬, (b) C2-C5-알케닐 또는 C2-C5-알키닐, 또는 (c) C3-C5-사이클로알킬이고; R7a및 R7b는 각각 H이며, R7a및 R7b가 인접한 탄소원자와 결합되는 경우 이들은 연결되어 페닐 환을 형성할 수 있으며; R8a및 R8b는 독립적으로 (a) H, (b) COOR4, OCOR4, OH, 또는 아릴로 임의 치환된 C1-C4알킬, (c) C2-C4-알케닐, (d) OH, (e) -NO2, (f), (g) -C1-C4-알콕시, (h), (i) -NR4R23, (j) -할로 (Cl, F, Br), (k) -CF3, (l) -CO2R4, (m) 상기에서 정의한 바와 같은 -CO-아릴, (n) -S(O)x-C1-C4-알킬, (o) -SO2-NH-C1-C4-알킬, (p) 상기에서 정의한 바와 같은 -SO20-NH-아릴 (q)(r) 상기에서 정의한 바와 같은 -아릴, 또는 (s) -NR4-CONR4R23이고 ; X는 단일 결합 또는 -CO-이며; r은 1인 일반식 (I)의 화합물.
- 약제학적으로 허용되는 담체 및 약제학적으로 유효한 양의 제1항의 화합물을 함유함을 특징으로 하는, 고혈압 치료에서 유용한 약제학적 조성물.
- 제5항에 있어서, 고혈압치료제 또는 이뇨제 또는 안지오텐신 전환효소, 또는 아밀로라이드, 아테놀올, 벤드로플루메티아지드, 크로로탈리돈, 클로로티아지드, 클로니틴, 크립텐아민 아세테이트 및 크립텐아민 탄네이트, 데세르피딘, 디아족사이드, 구안에티덴 설페이트, 하이드랄아진 하이드로클로라이드, 하이드로클로로티아지드, 메톨라존, 메토프롤로타타레이트, 메티클로티아지드, 메틸도파, 메틸도페이트 하이드로클로라이드, 미녹시딜, 파르길린 하이드로클로라이드, 폴리티아지드, 프라조신, 프로프라놀롤, 라우볼피아 세르펜티나(rauwolfia Ser Pentina), 레신아민, 레세르핀, 나트륨 니트로푸루시드, 스피로노락톤, 티몰롤 말리에이트, 트리플로르메티아지드, 트리메토판 캄실레이트, 벤조티아지드, 퀴네타존, 티크리나판, 트리암테렌, 아세트아졸아미드, 아미노필린, 사이클로티아지드 에타크린산, 푸로세미드, 메레톡실린 프로카인, 나트륨 에타크리네이트, 랍토프릴, 텔라프릴 하이드로클로라이드, 에날라프릴, 에날라프릴랏, 포시노프릴 나트륨, 리시노프릴, 펜토프릴, 퀴나프릴하이드로 클로라이드, 라아프릴, 테프로티드, 조페노프릴 칼슘, 디플후시날, 딜티아젬, 펠로디핀, 니카르디핀, 니페디핀, 닐루디핀, 니모디핀, 니솔디핀 및 니트렌디핀으로 이루어진 그룹 뿐만아라 이의 첨가 혼합물 및 배합물중에서 선택된 그룹인 칼슘 채널 차단제를 포함하는 조성물.
- 안과학적으로 허용되는 담체, 및 고안압을 방지하기에 유효한 양의 제1항에 따른 화합물을 함유하는, 고안압을 치료하기 위한 안과학적 제형.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37521789A | 1989-07-03 | 1989-07-03 | |
US375217 | 1989-07-03 | ||
US375,217 | 1989-07-03 | ||
US53789190A | 1990-06-18 | 1990-06-18 | |
US537,891 | 1990-06-18 | ||
US537891 | 1990-06-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910002810A true KR910002810A (ko) | 1991-02-26 |
KR0163586B1 KR0163586B1 (ko) | 1998-12-01 |
Family
ID=27006967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900009994A KR0163586B1 (ko) | 1989-07-03 | 1990-07-03 | 안지오텐시 ii 길항제로서의 치환된 퀴나졸리논 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0411766B1 (ko) |
JP (1) | JPH03115271A (ko) |
KR (1) | KR0163586B1 (ko) |
AT (1) | ATE100448T1 (ko) |
AU (1) | AU626699B2 (ko) |
CA (1) | CA2020073A1 (ko) |
DE (1) | DE69006131T2 (ko) |
FI (1) | FI903331A0 (ko) |
IE (1) | IE64244B1 (ko) |
IL (1) | IL94915A (ko) |
NO (1) | NO178969C (ko) |
NZ (1) | NZ234327A (ko) |
PT (1) | PT94568B (ko) |
ZA (1) | ZA905150B (ko) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240928A (en) * | 1989-07-03 | 1993-08-31 | Merck & Co., Inc. | Substituted quinazolinones as angiotensin II antagonists |
US5449682A (en) * | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
CA2037630C (en) * | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
FR2681067B1 (fr) * | 1991-09-10 | 1993-12-17 | Elf Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
CA2051705A1 (en) * | 1990-06-19 | 1991-12-20 | Kiyoaki Katano | Pyridine derivatives having angiotensin ii antagonism |
CA2053148A1 (en) * | 1990-10-16 | 1992-04-17 | Karnail Atwal | Dihydropyrimidine derivatives |
US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
IL100917A0 (en) * | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
EP0502575A1 (en) * | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
US5385894A (en) * | 1991-03-06 | 1995-01-31 | Merck & Co., Inc. | Disubstituted 6-aminoquinazolinones |
US5187179A (en) * | 1991-03-22 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
DE4110019C2 (de) * | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
US5157040A (en) * | 1991-04-05 | 1992-10-20 | Merck & Co., Inc. | Substituted quinolines as angiotensin ii antagonists |
US5151435A (en) * | 1991-04-08 | 1992-09-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating an indole or dihydroindole |
US5252574A (en) * | 1991-04-26 | 1993-10-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted thiophene or furan |
US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5162325A (en) * | 1991-05-07 | 1992-11-10 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
US5238942A (en) * | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
US5162340A (en) * | 1991-05-10 | 1992-11-10 | Merck & Co., Inc. | Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists |
NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
IL101860A0 (en) * | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
US5175164A (en) * | 1991-06-05 | 1992-12-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted indole or dihydroindole |
GB9113626D0 (en) * | 1991-06-25 | 1991-08-14 | Ici Plc | Heterocyclic compounds |
GB9113628D0 (en) * | 1991-06-25 | 1991-08-14 | Ici Plc | Heterocyclic derivatives |
IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
TW251288B (ko) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
WO1993003040A1 (en) * | 1991-08-05 | 1993-02-18 | Taisho Pharmaceutical Co., Ltd. | Thienopyrimidin-4-one derivative |
US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
CA2079982A1 (en) * | 1991-10-07 | 1993-04-08 | Stephen E. De Laszlo | Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists |
US5236925A (en) * | 1991-10-24 | 1993-08-17 | American Home Products Corporation | Fused pyrimidines as angiotensin II antagonists |
US5234936A (en) * | 1991-10-24 | 1993-08-10 | American Home Products Corporation | Pyrimidocycloalkanes as a ii antagonists |
US5149699A (en) * | 1991-10-24 | 1992-09-22 | American Home Products Corporation | Substituted pyridopyrimidines useful as antgiotensin II antagonists |
US5283242A (en) * | 1991-10-24 | 1994-02-01 | American Home Products Corporation | Substituted benzimidazoles and quinazolines as antihypertensives |
US5256781A (en) * | 1991-10-24 | 1993-10-26 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
US5212177A (en) * | 1991-12-16 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Indole and benzimidazole-substituted dihydropyrimidine derivatives |
US5234923A (en) * | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
US5350752A (en) * | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
GR1001386B (el) * | 1991-12-24 | 1993-10-29 | Takeda Chemical Industries Ltd | Ετεροκυκλικές ενώσεις. |
AU3440693A (en) * | 1992-01-17 | 1993-08-03 | Syntex (U.S.A.) Inc. | Substituted 1-isoquinolone derivatives as angiotensin II antagonists |
US5204354A (en) * | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
US5378704A (en) * | 1992-04-15 | 1995-01-03 | E. R. Squibb & Sons, Inc. | Non-peptidic angiotensin-II-receptor-antagonists |
US5236916A (en) * | 1992-05-26 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Oxadiazinone substituted indole and benzimidazole derivatives |
US5292741A (en) * | 1992-08-18 | 1994-03-08 | Merck & Co., Inc. | Macrocycles incorporating quinazolinones |
IT1263804B (it) * | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
US5420133A (en) * | 1993-03-19 | 1995-05-30 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5284853A (en) * | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5288720A (en) * | 1993-04-23 | 1994-02-22 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5294611A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5292734A (en) * | 1993-04-23 | 1994-03-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5281602A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetrahydro-pyrido[4,3-D]pyrimidin-4(3H)-ones |
US5286729A (en) * | 1993-04-23 | 1994-02-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5296480A (en) * | 1993-04-23 | 1994-03-22 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetra-hydro-pyrido[4,3]pyrimidin-4(3H)-ones |
US5292742A (en) * | 1993-04-23 | 1994-03-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5284852A (en) * | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted quinazolinones |
US5281603A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5281604A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted quinazolinones |
US5338740A (en) * | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
US5409926A (en) * | 1993-07-19 | 1995-04-25 | Merck & Co., Inc. | AT-2 antagonist inhibition of vascular restenosis |
US5338736A (en) * | 1993-10-07 | 1994-08-16 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted quinazolinones |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
KR100300566B1 (ko) * | 1994-09-17 | 2001-11-22 | 조생현 | 피리미디논유도체와그의제조방법및용도 |
US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
BR9908474A (pt) | 1998-03-04 | 2000-12-05 | Takeda Chemical Industries Ltd | Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica |
AU767456B2 (en) * | 1998-07-06 | 2003-11-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
FI20010233A0 (fi) | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
CA2466659A1 (en) | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticancer agents |
CA2502302A1 (en) * | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
US8551950B2 (en) * | 2006-03-20 | 2013-10-08 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis of inflammatory pain |
CN101522676A (zh) | 2006-10-05 | 2009-09-02 | Cv医药有限公司 | 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 |
US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010056230A1 (en) * | 2008-10-15 | 2010-05-20 | Cv Therapeutics, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3936453A (en) * | 1974-01-28 | 1976-02-03 | Sandoz, Inc. | 1-Substituted-2-disubstituted aminoquin azolin-4(1h)-ones |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4820843A (en) * | 1987-05-22 | 1989-04-11 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
-
1990
- 1990-06-28 CA CA002020073A patent/CA2020073A1/en not_active Abandoned
- 1990-06-29 DE DE69006131T patent/DE69006131T2/de not_active Expired - Fee Related
- 1990-06-29 EP EP90307126A patent/EP0411766B1/en not_active Expired - Lifetime
- 1990-06-29 AT AT90307126T patent/ATE100448T1/de not_active IP Right Cessation
- 1990-06-29 IL IL9491590A patent/IL94915A/xx not_active IP Right Cessation
- 1990-07-02 ZA ZA905150A patent/ZA905150B/xx unknown
- 1990-07-02 IE IE240190A patent/IE64244B1/en not_active IP Right Cessation
- 1990-07-02 PT PT94568A patent/PT94568B/pt not_active IP Right Cessation
- 1990-07-02 FI FI903331A patent/FI903331A0/fi not_active Application Discontinuation
- 1990-07-02 NZ NZ234327A patent/NZ234327A/xx unknown
- 1990-07-02 AU AU58607/90A patent/AU626699B2/en not_active Ceased
- 1990-07-02 NO NO902954A patent/NO178969C/no unknown
- 1990-07-03 KR KR1019900009994A patent/KR0163586B1/ko not_active IP Right Cessation
- 1990-07-03 JP JP2176112A patent/JPH03115271A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA905150B (en) | 1991-04-24 |
FI903331A0 (fi) | 1990-07-02 |
EP0411766B1 (en) | 1994-01-19 |
NO902954D0 (no) | 1990-07-02 |
DE69006131T2 (de) | 1994-07-21 |
KR0163586B1 (ko) | 1998-12-01 |
PT94568B (pt) | 1997-03-31 |
IE902401A1 (en) | 1991-06-19 |
ATE100448T1 (de) | 1994-02-15 |
DE69006131D1 (de) | 1994-03-03 |
NO902954L (no) | 1991-01-04 |
AU626699B2 (en) | 1992-08-06 |
PT94568A (pt) | 1991-03-20 |
NO178969C (no) | 1996-07-10 |
CA2020073A1 (en) | 1991-01-04 |
EP0411766A1 (en) | 1991-02-06 |
NZ234327A (en) | 1992-12-23 |
IL94915A0 (en) | 1991-04-15 |
IE64244B1 (en) | 1995-07-26 |
NO178969B (no) | 1996-04-01 |
JPH03115271A (ja) | 1991-05-16 |
AU5860790A (en) | 1991-01-03 |
IL94915A (en) | 1994-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910002810A (ko) | 안지오텐신 ii 길항제로서의 치환된 퀴나졸리논 | |
KR890002430B1 (ko) | 플라바놀리그난의 인지질과의 복합체의 제조 방법 | |
KR850000584B1 (ko) | 수성 콜로이드 조성물의 제조방법 | |
FI116999B (fi) | Menetelmä farmaseuttisen emulsion valmistamiseksi | |
DE3777554D1 (de) | Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten. | |
AU2017250507B2 (en) | Methods of treatment using chlorotoxin conjugates | |
JPH0374369A (ja) | アンギトテンシン2拮抗剤 | |
EA012240B1 (ru) | Пролекарства ингибиторов киназы pi-3 | |
DE69021755T2 (de) | Benzopyranderivate und Verfahren zu ihrer Herstellung. | |
MX9202849A (es) | Analogos del agente antitumoral rebecamicina. | |
KR970704710A (ko) | 트리아졸 화합물 및 도파민 D₃리간드로서의 그의 용도(Triazole Compounds and Their Use as Dopamine-D₃-Ligands) | |
DK392788A (da) | Arylderivater | |
HU902672D0 (en) | Pesticide compositions and process for the preparation of 1-aryl-imidazoles used as active inhgredient | |
DK361587A (da) | Thiazolyleddikesyrederivater og fremgangsmaader til fremstilling deraf | |
EP0454078B1 (en) | Dual functioning excipient for metal chelate contrast agents | |
EP0270093A3 (en) | Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties | |
SE440360B (sv) | Bis-(2-ammonium-2-hydroximetyl-1,3-propandiol)-(2r-cis)-(3-metyloxiranyl)-fosfanat, sett att framstella denna forening och farmaceutisk komposition innehallande foreningen | |
KR910020004A (ko) | 이소크로만 유도체 | |
JPH0259835B2 (ko) | ||
KR970704703A (ko) | 제조 활성을 갖는 피라진 유도체(Herbicidal Pyrazine Derivatives) | |
NO902318D0 (no) | Fremgangsmaate for fremstilling av aminosubstituerte heterocykliske forbindelser. | |
RU99100377A (ru) | Новые ароматические производные, замещенные рибозой, способ их получения и их применение в качестве лекарств | |
SE8004869L (sv) | Svavelhaltiga isokinolinderivat, sett for deras framstellning och farmaceutiska beredningar innehallande dem | |
AU7529587A (en) | Process for preparation of pristinamycin 11b derivatives | |
IE904088A1 (en) | "Process for the production of aqueous mixed micelle solutions" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |